LAS VEGAS, Aug. 20, 2025 /PRNewswire/ — DelveInsight’s Minimal Residual Disease Testing Market Insights report provides the current and forecast market analysis, individual leading minimal residual disease testing companies’ market shares, challenges, minimal residual disease testing market drivers, barriers, trends, and key market minimal residual disease testing companies in the market.
Key Takeaways from the Minimal Residual Disease Testing Market Report
* As per DelveInsight estimates, North America is anticipated to dominate the global minimal residual disease testing market during the forecast period.
* In the test type segment of the minimal residual disease testing market, the polymerase chain reaction category accounted for the largest market share in 2024.
* Notable minimal residual disease testing companies such as F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and several others, are currently operating in the minimal residual disease testing market.
* In June 2025, QIAGEN expanded its minimal residual disease (MRD) testing portfolio through new strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics. These collaborations aim to strengthen QIAGEN’s presence in MRD testing for both solid tumors and blood cancers.
* In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two key solutions. The first, Labcorp Plasma Detect, is designed to help assess the risk of disease recurrence in patients with stage III colon cancer. The second, PGDx elio plasma focus Dx, is the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, aimed at identifying patients who may benefit from targeted therapies.
* In January 2025, Adaptive Biotechnologies Corporation announced a multi-year exclusive strategic commercial collaboration aimed at advancing MRD monitoring for patients with select blood cancers. The partnership combines Adaptive’s clonoSEQ MRD test with NeoGenomics’ COMPASS and CHART assessment services, providing clinicians and patients with deeper insights throughout the treatment journey.
To read more about the latest highlights related to the minimal residual disease testing market, get a snapshot of the key highlights entailed in the Global Minimal Residual Disease Testing Market Report
Read more on wallstreet:online
